Skip to main content

Table 5 6-month post-index all-cause healthcare utilization stratified by drug-drug interaction status

From: A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

 

Pregabalin

Duloxetine

No

DDI

 

No

DDI

 

DDI present

present

 

DDI present

present

 
 

n = 433

n = 13

Pvalue*

n = 193

n = 253

Pvalue*

All-Cause Inpatient Visits

      

Members with Hospitalization

123 (28.4%)

1 (7.7%)

**

49 (25.4%)

90 (35.6%)

0.0214

Hospitalizations Per Member, Mean (SD)

0.9 (2.8)

0.1 (0.3)

0.0897

0.5 (1.9)

1.3 (3.9)

0.0059

All-Cause Emergency Room Visits

      

Members with Visit

100 (23.1%)

3 (23.1%)

**

40 (20.7%)

83 (32.8%)

0.0047

Visits per Member, Mean (SD)

0.5 (1.2)

0.6 (1.2)

0.8068

0.4 (1.0)

0.7 (1.2)

0.0035

All-Cause Outpatient Visits (non-physical therapy)

      

Members with Visit

427 (98.6%)

13 (100.0%)

**

190 (98.4%)

250 (98.8%)

**

Visits per Member, Mean (SD)

14.6 (12.6)

12.8 (9.1)

0.7728

15.2 (13.6)

17.3 (11.1)

0.0044

All-Cause Physical Therapy Visits

      

Members with Visit

57 (13.2%)

2 (15.4%)

**

33 (17.1%)

32 (12.6%)

0.1869

Visits per Member, Mean (SD)

0.8 (3.1)

0.3 (0.9)

0.8733

1.0 (4.1)

0.9 (3.5)

0.2342

  1. *All P values for categorical variables calculated using Chi Square tests. All P values for continuous variables calculated using Wilcoxon Rank-Sum tests.
  2. **Expected Counts <5. Chi-square test may not be appropriate.
  3. DDI, Drug-Drug Interaction.
  4. SD, Standard Deviation.